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Introduction
Damage to tissues and organs is frequent in the life of vertebrates: 
tissues can be ripped, squashed, or wounded by mechanical 
forces, mishaps, or predators. Freezing or burns, chemical insults 
(strong acids or bases or cytotoxic poisons produced by invading 
bacteria), radiation, or the withdrawal of oxygen and/or nutrients 
can also kill cells. Thus, the ability to repair damaged tissues is 
essential for evolutionary success. Very often the new cells that 
replace the dead ones migrate from specifi  c niches within the tis-
sue or from distant districts such as the bone marrow. Although 
the mechanism of cell migration has been intensely studied, the 
orchestration of the physiological responses that bring the rel-
evant cells to the required sites is much less understood.
We and others have found that high mobility group box 1 
(HMGB1), an abundant component of the cell nucleus, when 
present in the extracellular space, signals tissue damage (Bianchi, 
2007). HMGB1 is released by cells undergoing necrosis (acci-
dental cell death) but not by cells undergoing apoptosis (Scaffi  di 
et al., 2002). Extracellular HMGB1 then promotes the ingression 
of infl  ammatory cells (Scaffi  di et al., 2002), but also the migra-
tion and proliferation of stem cells (Palumbo et al., 2004; Limana 
et al., 2005). Thus, HMGB1 has the expected characteristics of a 
signal that can orchestrate tissue regeneration, although it is not 
expected to be the only one (Bianchi, 2007).
In particular, we previously described that extracellular 
HMGB1 can attract mesoangioblasts, both in vitro and in vivo 
(Palumbo et al., 2004). Mesoangioblasts are a specifi  c population 
of mesodermal stem cells that are associated with the walls of fetal 
and postnatal vessels (Minasi et al., 2002). They grow extensively 
in culture and can differentiate into most mesodermal cell types. 
When injected into the general circulation of dystrophic mice and 
dogs, they migrate into muscles and contribute to their regenera-
tion and functional recovery (Sampaolesi et al., 2003, 2006).
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T
issue damage is usually followed by healing, as both 
differentiated and stem cells migrate to replace dead 
or damaged cells. Mesoangioblasts (vessel-associated 
stem cells that can repair muscles) and ﬁ  broblasts migrate 
toward soluble factors released by damaged tissue. Two 
such factors are high mobility group box 1 (HMGB1), a nu-
clear protein that is released by cells undergoing unsched-
uled death (necrosis) but not by apoptotic cells, and stromal 
derived factor (SDF)–1/CXCL12. We ﬁ   nd that HMGB1 
activates the canonical nuclear factor κB (NF-κB) pathway 
via extracellular signal-regulated kinase phosphorylation. 
NF-κB signaling is necessary for chemotaxis toward 
HMGB1 and SDF-1/CXCL12, but not toward growth fac-
tor platelet-derived growth factor, formyl-met-leu-phe 
(a peptide that mimics bacterial invasion), or the archetypal 
NF-κB–activating signal tumor necrosis factor α. In dys-
trophic mice, mesoangioblasts injected into the general 
circulation ingress inefﬁ  ciently into muscles if their NF-κB 
signaling pathway is disabled. These ﬁ  ndings suggest that 
NF-κB signaling controls tissue regeneration in addition 
to early events in inﬂ  ammation.
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Here, we have investigated the signaling pathways that ac-
tivate cell migration toward extracellular HMGB1 and allow meso-
angioblasts to navigate to damaged muscles. HMGB1 is known 
to activate MAPKs and nuclear factor κB (NF-κB); we show 
that NF-κB activation proceeds via extracellular signal-regulated 
 kinase (ERK) phosphorylation. Surprisingly, mesoangioblasts and 
fi  broblasts do not migrate toward HMGB1 if NF-κB activation is 
blocked. This same NF-κB dependency applies to stromal derived 
factor (SDF)–1/CXCL12, which also directs the migration of stem 
cells, but not to TNF-α, the archetypal NF-κB activating signal.
Results and discussion
Fibroblasts respond chemotactically 
to HMGB1
Mesoangioblasts provide an excellent model to investigate cell 
navigation to damaged tissues in living animals; however, em-
bryonic fi  broblasts from genetically modifi  ed mice allow the 
unequivocal identifi  cation of the components of the signaling 
pathways activated by individual chemoattractants.
Fibroblast cell lines such as 3T3 and wild-type (wt) mouse 
embryonic fi  broblasts (MEFs), either primary or immortalized 
with polyoma large T antigen (Calogero et al., 1999), respond 
chemotactically to HMGB1 in Boyden chambers (Fig. 1 A). 
The migration is directional, as shown by the tracking of living 
3T3 fi  broblasts in chemoattractant gradients formed between 
the inner well and the external ring chamber of a Dunn chemo-
taxis apparatus (Fig. 1 B). Most cells migrated toward HMGB1 
or PDGF, with mean paths of  70 and 55 μm, respectively, 
but were immobile or moved randomly (mean path of 20 μm) 
in the absence of chemoattractants (Fig. 1 C). Movement oc-
curred within  10, 15, and 25 min in the presence of HMGB1, 
PDGF, and serum-free medium, respectively (Fig. 1 D). Simi-
lar results were obtained with primary and immortalized MEFs 
(unpublished data).
NF-𝗋B is activated in response to HMGB1 
via an ERK-dependent mechanism
Extracellular HMGB1 has been reported to engage multiple re-
ceptors, including the receptor for advanced glycation end pro-
ducts (RAGE; Hori et al., 1995) and Toll-like receptors 2 and 4 
(Park et al., 2004). RAGE has been reported to activate MAPKs; 
both RAGE and Toll-like receptors activate NF-κB (Bonizzi 
and Karin, 2004; Bierhaus et al., 2005).
Figure 1.  Fibroblasts migrate in response to HMGB1. (A) Cell 
migration toward 10 ng/ml PDGFBB and 30 ng/ml HMGB1 
was tested in Boyden chambers for 3 h for 3T3 ﬁ  broblasts, 
primary ﬁ  broblasts derived from wt embryonic day 14.5 mouse 
embryos, and ﬁ  broblasts immortalized with large T antigen. 
Each error bar represents the mean ± SD of triplicate samples. 
The difference between control and chemoattractants is statis-
tically signiﬁ  cant (P < 0.01). Each cell type was tested at least 
three times. (B) In Dunn chambers, cells migrate directionally 
toward the source of HMGB1 and PDGFBB (asterisk) and 
move randomly in the absence of chemoattractant. (C) Length 
of the paths of migrating cells under different conditions. Each 
error bar represents the mean ± SD of triplicate samples. The 
difference between control and chemoattractants is statisti-
cally signiﬁ  cant (P < 0.01). This experiment was repeated 
three times. (D) Time elapsed before cell movement. Each 
point represents one cell.NF-κB ACTIVATION IN MIGRATING CELLS • PALUMBO ET AL. 35
We had previously shown that U0126, a specifi  c inhibitor 
of MAPK/ERK kinase (MEK) 1/2, which phosphorylates ERKs, 
abrogates the migration of smooth muscle cells in response to 
HMGB1 (Degryse et al., 2001). Likewise, HMGB1 induced the 
rapid phosphorylation of ERK1/2 in 3T3 fi  broblasts (Fig. 2 A) 
and U0126 inhibited the HMGB1-induced migration (Fig. 2 B).
NF-κB is a family of transcription factors consisting of di-
mers of fi  ve different proteins—p65 (RelA), RelB, c-Rel, NF-κB1 
(p105/p50), and NF-κB2 (p100/p52)—and is essential for most 
innate and adaptive immune responses (Pomerantz and Baltimore, 
2002; Bonizzi and Karin, 2004). Different types of inactive 
NF-κB cytoplasmic complexes are activated by a host of stress 
stimuli by two routes. The classical or canonical NF-κB pathway 
begins with the activation of NEMO/IκB kinase γ (IKK), IKKβ, 
and IKKα in a cytoplasmic IKK signalsome complex. IKKβ 
phosphorylates the NF-κB inhibitor IκBα at two amino-  terminal 
Figure 2.  HMGB1 induces NF-𝗋B activation via an ERK-
dependent mechanism. (A) 3T3 ﬁ  broblasts  were  stimulated 
with 100 ng/ml HMGB1 or 10 ng/ml PDGFBB for 5, 15, 30, 
or 60 min, and total cell proteins were analyzed by Western 
blot. ERK1/2 activation was visualized with anti–phospho-
ERK antibody (pERK1/2). Stripped blots were reprobed with 
antibodies against total ERK (ERK1/2). Results are repre-
sentative of three independent experiments. (B) U0126 in-
hibits HMGB1-induced cell migration. 3T3 ﬁ  broblasts were 
pretreated with or without 10 μM of the MEK1/2 inhibitor 
U0126 for 30 min and were allowed to migrate in Boyden 
chambers for 3 h toward 30 ng/ml HMGB1 or no stimulus. 
Each error bar represents the mean ± SD of triplicate sam-
ples. This experiment was repeated three times. (C) HMGB1 
induces NF-κB nuclear translocation. 3T3 ﬁ  broblasts grown 
on coverslips were serum starved for 16 h and stimulated with 
100 ng/ml HMGB1 or 20 ng/ml TNF-α for 20 and 10 min, 
respectively. Cells were ﬁ  xed and immunostained indirectly 
for p65/RelA. (D) IκBα is phosphorylated in 3T3 ﬁ  broblasts 
exposed to HMGB1 or TNF-α. Cells were lysed in SDS-PAGE 
loading buffer at the indicated times; proteins were Western 
blotted with rabbit polyclonal antibodies against mouse 
pIκBα or mAb against β-actin. (E) MEK inhibitor U0126 pre-
vents NF-κB nuclear translocation. 3T3 ﬁ  broblasts grown on 
coverslips were serum starved for 16 h, exposed where indi-
cated to U0126, and stimulated 30 min later with 100 ng/ml 
HMGB1. After 20 min, cells were ﬁ  xed and immunostained 
indirectly for p65/RelA. (F) The MEK inhibitor U0126 im-
pairs IκBα phosphorylation. 3T3 ﬁ  broblasts were exposed to 
30 μM U0126 for 30 min and stimulated with 100 ng/ml 
HMGB1 for 20 min. Total cellular proteins were subjected 
to Western blotting with rabbit polyclonal antibodies against 
mouse pIκBα or mAb against β-actin.JCB • VOLUME 179 • NUMBER 1 • 2007  36
serines, targeting it for polyubiquitination and proteasomal 
destruction. This leads to the nuclear trans  location of NF-κB 
p50/p65 and p50/c-Rel heterodimers and trans  cription of their 
target genes. The alternative or noncanonical pathway is IκBα 
independent and depends solely on IKKα, which phosphorylates 
p100 to promote its proteasomal processing to mature p52, thereby 
causing nuclear translocation of RelB/p52 heterodimers and a 
subset of p50/p65 heterodimers residing in cytoplasmic p100 
complexes (Basak et al., 2007).
Indirect immunofl  uorescence showed that 3T3 fi  broblasts 
accumulate p65 in their nuclei in response to extracellular HMGB1, 
but to a lesser extent than in response to TNF-α (Fig. 2 C). IκBα 
phosphorylation on Ser-32 and Ser-36 peaked between 15 and 
30 min after exposure to extracellular HMGB1 (Fig. 2 D). These 
data indicate that HMGB1 activates the canonical NF-κB pathway.
We next tested whether the activation of ERK and NF-κB 
in response to HMGB1 are parallel or consecutive events. In the 
presence of HMGB1 and U0126, NF-κB is not translocated to 
the nucleus of 3T3 cells (Fig. 2 E) and IκBα phosphorylation 
is impaired (Fig. 2 F). Thus, HMGB1 activates the canonical 
NF-κB pathway via ERK.
NF-𝗋B activation is necessary for cell 
migration in response to HMGB1
ERK participates in cytoskeleton remodeling, but NF-κB is not 
expected to be involved (Ridley et al., 2003). To formally rule 
out a role for canonical NF-κB in HMGB1-elicited cell migra-
tion, we tested immortalized MEFs, genetically defi  cient in both 
p50 and p65. To our surprise, p50/p65 knockout fi  broblasts 
failed to migrate toward HMGB1, although they migrated as ex-
pected toward PDGF (Fig. 3 A). In further support of this result, 
wt MEFs stably expressing an IκBα super-repressor (IκBαSR), 
which cannot be phosphorylated and degraded (Brockman et al., 
1995), did migrate as expected toward PDGF but not toward 
HMGB1 (Fig. 3 A). These experiments indicate that the clas-
sical NF-κB pathway controls HMGB1-elicited cell migration, 
but the possibility remains that NF-κB dimers might interact 
with the cytoskeleton instead of controlling transcription.
We then showed that SN50, a cell-permeable peptide that 
competes with the nuclear transport of p50 (Lin et al., 1995), 
interfered in HMGB1-elicited cell migration, whereas the 
scrambled control peptide SN50M had no effect (Fig. 3 B). 
Signifi  cantly, neither SN50 nor SN50M affected PDGF-elicited 
cell migration (unpublished data). These results suggest that the 
nuclear function of NF-κB is required for cell migration toward 
HMGB1. Indeed, fi  broblasts pretreated for 30 min with cyclohex-
imide, an inhibitor of protein synthesis, or 5,6-dichloro-1-β-D-
ribobenzimidazole (DRB), an inhibitor of transcription, failed 
to migrate toward HMGB1 but migrated toward 1% serum (Fig. 
3 C). Similar results were obtained with endothelial and smooth 
muscle cells (unpublished data). These data show unequivocally 
that the transcriptional activity of NF-κB is necessary for cell 
migration toward HMGB1.
NF-𝗋B activation is necessary for 
mesoangioblast migration toward 
HMGB1 and SDF-1/CXCL12
We next investigated whether NF-κB activation is also required 
for the HMGB1 migration response of mesoangioblasts. HMGB1 
induces p65 accumulation in mesoangioblast nuclei, although 
to a lesser extent than TNF-α (Fig. 4 A). In addition, HMGB1 
induced the transcriptional activation of the endogenous IκBα 
gene, a direct target of NF-κB (Fig. 4 B).
It was previously shown that mesoangioblasts respond 
chemotactically to several cytokines present in dystrophic mus-
cle, including SDF-1/CXCL12 and TNF-α (Galvez et al., 2006). 
TNF-α is a well-known activator of the NF-κB pathway (Fig. 4, 
A–C); CXCL12 has been reported to activate a variety of path-
ways, including NF-κB, in pre-B cell lines (Ganju et al., 1998). 
Indeed, CXCL12 induces p65 nuclear translocation in meso-
angioblasts (Fig. 4 C).
NF-κB activation and mesoangioblast migration are causally 
related, but only in response to a subset of chemoattractants. In fact, 
mesoangioblasts transiently expressing IκBαSR showed an im-
paired chemotactic response to HMGB1 and CXCL12, whereas 
their response to TNF-α was unaffected (Fig. 4, D and E).
Figure 3. NF-𝗋B controls HMGB1-induced cell 
migration. Cells migrated in Boyden chambers 
for 3 h toward 10 ng/ml PDGFBB, 30 ng/ml 
HMGB1, or no chemoattractant (medium alone). 
(A) Immortalized p50/p65−/− MEFs and 
  immortalized wt MEFs stably transfected with 
IκBαSR do not migrate toward HMGB1. Each 
error bar represents the mean ± SD of triplicate 
samples; results were replicated three times. 
(B) Fibroblasts were pretreated for 30 min with 
the indicated concentrations of SN50 or the 
scrambled peptide SN50M, and cell migra-
tion was assayed toward HMGB1. Error bars 
represent the mean of duplicate samples ± SD; 
results were replicated three times. The effect 
of treatment (SN50 vs. untreated and SN50M) 
and dose are signiﬁ  cant (P < 0.05, analysis of 
variance). (C) Fibroblasts were pretreated for 
30 min with 50 μM cycloheximide or 25 μM 
DRB (+) or no addition (−) and subjected to 
migration assays. Bars represent the mean of 
duplicate samples ± SD; results were replicated 
three times. *, P < 0.05.NF-κB ACTIVATION IN MIGRATING CELLS • PALUMBO ET AL. 37
Mesoangioblasts need NF-𝗋B activation 
to ingress into damaged muscles
We next tested whether NF-κB activity is required for meso-
angioblast ingression into the diseased muscles of α-sarcoglycan 
(α-SG) null dystrophic mice. Mesoangioblasts were transfected 
with plasmids expressing GFP and IκBαSR, or GFP alone. 48 h 
after transfection  25% of cells in each population were fl  uo-
rescent. We injected 450,000 cells into the femoral artery of 
dystrophic mice (two per group). 6 h later we recovered fi  lter 
organs (liver, spleen, and lung) and muscles (gastrocnemius, 
quadriceps, and tibialis) from the side of injection and the con-
tralateral leg. Mesoangioblasts had migrated within the tissues 
and had not simply positioned themselves within or just outside 
microvessels (Fig. 5, A and B).
Figure 4. NF-𝗋B activation is required for mesoangioblast migration toward HMGB1 and CXCL12, but not other chemoattractants. (A) 100 ng/ml HMGB1 
promotes nuclear translocation of p65 in mesoangioblasts. Paired images show DAPI (blue) and p65/RelA (detected via indirect immunoﬂ  uorescence; red). 
Stimulation with 20 ng/ml TNF-α is shown as positive control. (B) 100 ng/ml HMGB1 and 20 ng/ml TNF-α induce NF-κB–dependent transcription of the 
endogenous IκBα gene in mesoangioblasts. Absolute quantities are normalized to β-actin. Results are shown as the mean of duplicate samples ± SD and 
were replicated three times. (C) 100 ng/ml SDF-1/CXCL12 promote nuclear translocation of p65 in mesoangioblasts (shown as in A). (D) Mesoangioblast 
migration toward HMGB1 depends on NF-κB activation. Mesoangioblasts were transfected with vectors encoding IκBαSR and GFP (pMP9IκBαSR) or GFP 
alone (pMP9), grown for 48 h, and induced to migrate for 6 h in Boyden chambers toward 1% serum (FCS), 100 ng/ml HMGB1, 10 ng/ml PDGFBB, 0.1 nM 
fMLP, or no chemoattractant (control). Only ﬂ  uorescent cells were counted. Results are the mean of triplicate samples ± SD, and were replicated three times. 
*, P < 0.05. (E) Mesoangioblast migration toward 100 ng/ml CXCL12, but not 20 ng/ml TNF-α, depends on NF-κB activation. Results are the mean of 
triplicate samples ± SD; experiments were performed as described in D.JCB • VOLUME 179 • NUMBER 1 • 2007  38
To estimate the fraction of transfected mesoangioblasts 
arriving into the tissues, we quantifi  ed GFP mRNA in each organ 
and in the mesoangioblast populations before injection. In each 
of the muscles on the injected and contralateral sides, meso-
angioblasts expressing IκBαSR and GFP were substantially fewer 
than those expressing GFP alone (13 ± 0.1 vs. 32.0 ± 0.2%, 
P < 0.001, two-tailed t test; Fig. 5 C). In contrast, fi  lter organs 
contained more IκBαSR-expressing than control mesoangio-
blasts (20.0 ± 0.1 vs. 27.3 ± 1.9%, P < 0.05), which is consis-
tent with the notion that mesoangioblasts not homing to muscle 
are mostly trapped in fi  lter organs. This experiment was repli-
cated three times, with similar results. Interestingly, IκBαSR 
reduces mesoangioblast ingression into dystrophic muscle but 
does not abrogate it completely, which is consistent with our 
in vitro results showing that not all chemotactic responses require 
NF-κB activation.
The role of NF-𝗋B in cell migration 
and tissue repair
Collectively, our results indicate that the canonical NF-κB activa-
tion is required for migration of fi  broblasts and mesoangioblasts 
toward specifi  c chemoattractants associated with tissue damage. 
Figure 5. I 𝗋B𝗂SR impairs mesoangioblast ingression into the muscles of dystrophic mice. Mesoangioblasts were transfected with vectors encoding IκBαSR 
and GFP (pMP9IκBαSR) or GFP alone (pMP9), grown for 48 h, and injected intraarterially into two α-SG −/− dystrophic mice per group. After 6 h, mice 
were killed, and muscles and ﬁ  lter organs were collected. (A) The quadriceps muscle on the side injected with mesoangioblasts expressing GFP alone was 
excised, ﬁ  xed, immunostained for myosin and GFP, and imaged. Mesoangioblasts expressing GFP (green) are seen clustering at the margin of myoﬁ  ber 
fascicles and dispersed among the myoﬁ  bers within the fascicle. (B) Representative images from sections of gastrocnemius muscles and livers from mice 
  injected with mesoangioblasts expressing GFP alone or GFP and IκBαSR. Nuclei are stained with Hoechst (blue); GFP is stained green. (C) The number of 
mesoangioblasts migrating into indicated organs was inferred by RT-PCR quantiﬁ  cation of GFP expression. Results are expressed as a percentage of GFP 
signal in the speciﬁ  c tissue; GFP expression of the entire mesoangioblast cells population before injection is set equal to 100%. This experiment was repli-
cated three times.NF-κB ACTIVATION IN MIGRATING CELLS • PALUMBO ET AL. 39
Although NF-κB is well known to direct the synthesis of cyto-
kines and chemokines that induce the migration of immune 
effector cells, reports on its role in the migrating cells themselves 
are scarce. IκBαSR abrogates chemotaxis toward Fgf-7 in im-
mortalized human pancreatic ductal epithelial cells and in fi  bro-
blasts forcedly expressing the Fgf-7 receptor FGF123R/IIIb (Niu 
et al., 2007). In a clone of the human osteogenic sarcoma cell line 
forcedly expressing the leukotactin-1 receptor CCR1, leukotactin-1 
activates NF-κB to transcribe LZIP, and LZIP protein enhances 
cell migration by binding to CCR1 (Jang et al., 2007).
Our results also indicate that NF-κB activation is required 
for mesoangioblast ingression into damaged tissue, under con-
ditions corresponding to the procedures being developed for cell-
based therapies of muscular dystrophy (Sampaolesi et al., 2006). 
An important consequence of the requirement for NF-κB acti-
vation for tissue regeneration is that pharmacological regimens 
that suppress infl  ammation by interfering with NF-κB (includ-
ing corticosteroids, which are commonly prescribed to dystro-
phic patients) might also suppress tissue regeneration and interfere 
with stem-cell therapies.
NF-κB activation is not required for the mechanical ac-
tions involved in cell migration because it is not needed for mi-
gration toward PDGF or formyl-met-leu-phe (fMLP). Moreover, 
NF-κB activation is not required for migration toward TNF-α, 
the archetypal canonical NF-κB activating signal. HMGB1 and 
CXCL12 both contribute to tissue repair (Kollet et al., 2003; 
Limana et al., 2005; Galvez et al., 2006) and both belong to a 
small group of chemoattractants that direct the navigation of stem 
cells (Knaut et al., 2003; Palumbo et al., 2004; Guo et al., 2005; 
Galvez et al., 2006). We speculate that, mechanistically, the dif-
ference between HMGB1/CXCL12 and TNF-α may be caused 
by differences in the timing and intensity of NF-κB activation or 
the concomitant activation of other signaling pathways. Physio-
logically, the difference may refl  ect specifi  c requirements for 
the initiation and maintenance of migration of differentiated and 
stem cells in response to tissue damage.
Materials and methods
HMGB1 and reagents
Full-length, LPS-free recombinant HMGB1 protein was provided by HMG-
Biotech, human recombinant PDGFBB and TNF-α by R&D Systems, CXCL12 
by Preprotec, and ﬁ  bronectin by Roche. Anti–β-actin mAbs, fMLP, DRB, 
and cycloheximide were obtained from Sigma-Aldrich. U0126 and anti-
bodies against IκBα, pIκBα, ERK, and phospho-ERK were obtained from 
Cell Signaling Technology. Rabbit polyclonal antibodies against p65/RelA 
were obtained from Calbiochem and Santa Cruz Biotechnology, Inc. 
SN50 and SN50M were obtained from Calbiochem.
Cell culture and transfection
3T3 mouse ﬁ  broblasts were grown in DME supplemented with 10% FCS. 
Mesoangioblasts (D16 clone) were grown in DME, supplemented with 20% 
FCS. Immortalized MEFs, wt or deﬁ  cient for p50 and p65 (p50/p65 −/−; 
provided by A. Beg, H. Lee Mofﬁ  tt Cancer Center & Research Institute, 
Tampa, FL), were cultured in DME supplemented with 10% FCS, 10 mM 
Hepes, 50 μM β-mercaptoethanol, 10 mM nonessential amino acids, and 
10 mM sodium pyruvate. Primary and immortalized MEFs were obtained 
as described previously (Calogero et al., 1999). Constitutive expression of 
a transdominant IκBαSR in wt MEFs was obtained by retroviral transduc-
tion as previously described (Li et al., 2001; Li et al., 2002). A Moloney 
retroviral vector, which coexpresses an SV40 promoter-driven GFP gene 
and a long terminal repeat-driven IκBαSR Flag tagged at the amino termi-
nus, was generated by subcloning the Flag-tagged IκBαSR ORF isolated 
from the pcDNA4-Flag IκBαSR vector (Brockman et al., 1995; provided by 
D.W. Ballard, Vanderbilt University Medical Center, Nashville, TN) into 
the unique BamHI site of the MP9 Moloney retroviral vector, a derivative of 
the PINCO vector (Grignani et al., 1998; provided by L. Lanfrancone, 
Istituto FIRC di Oncologia Molecolare, Milan, Italy) in which the cytomega-
lovirus enhancer was replaced with the SV40 promoter/enhancer. Cells 
were transiently transfected with each of the aforementioned vectors using 
FuGENE 6 reagent, according to the manufacturer’s instructions (Roche).
Chemotaxis assays
Boyden chamber assays were performed as described previously (Palumbo 
et al., 2004). In the Dunn chamber, chemoattractants added to the outer 
well of the device diffuse across the bridge to the inner blind well and form 
a gradient within  30 min (Wells and Ridley, 2005). This apparatus al-
lows for determination of the direction of migration in relation to the direc-
tion of the gradient. In our experiments, the outer well of the Dunn chamber 
was ﬁ  lled with 10 ng/ml PDGFBB and 100 ng/ml HMGB1 or serum-free 
medium, and the concentric inner well contained only serum-free medium. 
Fibroblasts were seeded on coverslips coated with 50 ng/ml ﬁ  bronectin. 
Coverslips were inverted onto the chamber, and cell migration through the 
annular bridge between the concentric inner and outer wells was recorded 
with a microscope (Axiovert S100TV; Carl Zeiss MicroImaging, Inc.), with 
a still frame every 3 min for 6 h.
Western blotting and immunoﬂ  uorescence for signal transduction studies
Cells were serum starved for 16 h in DME and stimulated with 100 ng/ml 
HMGB1, 100 ng/ml CXCL12, or 20 ng/ml TNF-α for the indicated times. 
Western blotting was done as described previously (Palumbo et al., 2004). 
Indirect immunoﬂ   uorescence was done as described previously (Palumbo 
et al., 2004), using rabbit polyclonal anti-p65 antibody at 4°C and Alexa-
Fluor 594–conjugated goat anti–rabbit IgG (Invitrogen). Slides were mounted 
in 90% glycerol, 20 mM Tris, pH 8.8, and 0.5% p-phenylenediamine. Images 
were taken at 37°C on a DeltaVision system consisting of a microscope 
(Olympus IX70), PlanApo 40×/1.35 and 60×/1.4 oil immersion objectives 
(Olympus), and a camera (HQ CoolSnap; Roper Scientiﬁ  c). Image acqui-
sition and deconvolution (10 iterations) were done with Softworx 3.5.0 
(Applied Precision).
Real-time PCR
Mesoangioblasts (100,000 per well) were stimulated with 100 ng/ml 
HMGB1 or 20 ng/ml TNF-α for the indicated times. cDNA was obtained 
with Illustra RNAspin mini RNA isolation kit (GE Healthcare) and ampliﬁ  ed 
by real-time PCR on a LC480 instrument (Roche), using the relative quantiﬁ  -
cation software, with LightCycler 480 SYBR Green I Master mix and prim-
ers for mouse β-actin (T  G  A  C  G  G  G  G  T  C  A  C  C  C  A  C  A  C  T  G  T  G  C  C  C  A  T  C  T  A   and 
C  T  A  G  A  A  G  C  A  T  T  G  C  G  G  T  G  G  A  C  G  A  T  G  G  A  G  G  G  ) and IκBα (C  T  T  G  G  C  T  G  T-
G  A  T  C  A  C  C  A  A  C  C  A  G   and C  G  A  A  A  C  C  A  G  G  T  C  A  G  G  A  T  T  C  T  G  C  ).
Mesoangioblast ingression into dystrophic muscle
D16 mesoangioblasts were transfected with FuGene 6 (according to the 
manufacturer; Roche) with expression vectors encoding IκBαSR and GFP 
(pMP9IκBαSR) or GFP alone (pMP9), and grown for 48 h. The experiment 
was then conducted as previously described (Galvez et al., 2006). Cells 
were resuspended in PBS, and the same amount of cells (450,000 cells in 
25 μl) were subjected to RT-PCR for GFP expression, or injected into the 
exposed femoral artery of anesthetized α-SG −/− dystrophic female mice 
(two per group). After 6 h, mice were killed, and the amount of GFP ex-
pression was measured by RT-PCR in ﬁ  lter organs (liver, lung, and spleen) 
and muscles (tibialis, gastrocnemius, and quadriceps) on the injected and 
contralateral sides. Results are expressed as the percentage of GFP signal 
in the speciﬁ  c tissue, setting GFP expression before injection as 100%. 
Muscles and ﬁ  lter organs were also processed for immunostaining as de-
scribed previously (Galvez et al., 2006), using rabbit anti-GFP polyclonal 
antibody (Chemicon) and AlexaFluor 488–conjugated donkey anti–rabbit 
secondary antibody (Invitrogen) and mouse anti-myosin heavy chain mAb 
MF20 (Sampaolesi et al., 2003) and AlexaFluor 594–conjugated donkey 
anti–mouse secondary antibody (Invitrogen). Slides were mounted in ﬂ  uor-
escent mounting medium (DakoCytomation). Images were taken at room 
temperature with a microscope (CTR 6000; Leica) equipped with a 
40×/0.60 objective and a camera (DFC 350 FX; Leica); the acquisition 
software was LAS AF application suite 1.6.2 (Leica).
Digital images
Digital Images were elaborated using Photoshop 8.0 (Adobe); the luminosity 
of brightest and dimmest pixel in each channel were adjusted to obtain the JCB • VOLUME 179 • NUMBER 1 • 2007  40
best visual reproduction, taking care to maintain linearity in the brightness 
scale. Images were included in ﬁ  gures using Illustrator 11.0 (Adobe).
Statistical analysis
Pairwise comparisons between continuous data were done using unpaired 
two-tailed Student’s t test; statistical analysis involving more than two groups 
was done using an analysis of variance model. Prism 4.0b software was 
used (GraphPad Software, Inc.).
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